The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the nine months ended September 30, 2025 and September 30, 2024 (in thousands):


	Three Months Ended September 30, 2025		Three Months Ended September 30, 2024		Nine Months Ended September 30, 2025		Nine Months Ended September 30, 2024
License and other revenue	$	—	$	—	$	15,000	$	—
Less:
OX2R agonist program expenses	(35,562)		(11,744)		(88,336)		(26,696)
LockBody program expenses	(3,441)		(2,815)		(8,624)		(9,081)
Discontinued R&D program expenses	585		(16,165)		(3,524)		(44,784)
Other R&D expenses:
Personnel expenses¹	(7,370)		(4,393)		(19,749)		(14,893)
Research tax incentives	9,321		5,500		18,055		18,895
Other preclinical and clinical development expenses	(1,798)		(644)		(3,999)		(1,438)
General and administrative expenses¹	(8,331)		(7,691)		(25,017)		(23,260)
Share-based compensation	(7,194)		(8,453)		(23,026)		(25,218)
Interest and investment income	3,765		3,340		16,035		9,171
Interest expense	(2,890)		(2,557)		(8,651)		(7,611)
Other segment items²	(1,810)		3,664		2,808		2,281
Income tax expense	(166)		(608)		(2,341)		(1,794)
Consolidated net loss	$	(54,891)	$	(42,566)	$	(131,369)	$	(124,428)

¹ Excludes share-based compensation
² Other segment items includes non-operating income (expenses), net